ETP Ventures

SEIMEI is a premium brand of personalized nutrition and anti-aging technology. It has collaborated with Human Longevity Inc., an influential research institute in the field of intestinal health. China Baijia Medical, a longevity technology company, WuXi AppTec, a CRO, and Yipu, a user research company, have all joined forces. Ipsos Group (Ipsos), Silver Economic Think Tank Platform Ageclub, Zeno Technology (Establishing Senmei Zeno Synthetic Biology Joint Laboratory), and other industry leaders have reached a strategic agreement.

Deep Longevity, Inc. is a biotechnology company focused on advancing aging and longevity research through the development of aging clocks and biomarkers. Founded in 2016 and based in Hong Kong, the company offers a range of products including the Longevity Cloud, which hosts deep aging clocks, and Young.AI, a web and mobile application designed to assist individuals in monitoring their biological age. Deep Longevity also provides AgeMetric Reports for tracking longevity and employs an AI-based recommendation engine to suggest interventions for improving health outcomes. Its comprehensive approach incorporates various data types such as clinical blood tests, transcriptomic, proteomic, and microbiome information, enabling healthcare providers and aging centers to predict biological age with greater accuracy and support preventative medicine initiatives.

Dima Biotech is a tumor immunotherapy and monoclonal antibody developer, specializing in the development of recombinant monoclonal antibodies for tumor immune products and services. It has the unique RECmAb digital monoclonal antibody technology, which can be used to obtain a variety of genus and high quality. Monoclonal antibodies.

Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.